Ibrolipim
Names | |
---|---|
IUPAC name
diethyl {4-[(4-bromo-2-cyanophenyl)carbamoyl]benzyl}phosphonate | |
Identifiers | |
3D model (Jmol) | Interactive image |
ChemSpider | 116297 |
ECHA InfoCard | 100.162.319 |
KEGG | D03747 |
PubChem | 131601 |
UNII | 07H1561618 |
| |
| |
Properties | |
C19H20BrN2O4P | |
Molar mass | 451.25 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
verify (what is ?) | |
Infobox references | |
Ibrolipim (NO-1886) is a cholesterol lowering drug from the statin family, which acts as a lipoprotein lipase activator. The discovery of the “statin” mevalonic acid synthesis inhibitors focused new attention on control of blood lipid levels as a measure to stave off heart disease. A number of compounds have been found that treat elevated lipid levels by other diverse mechanisms. The phosphonic acid derivative ibrolipim is believed to lower those levels by accelerating fatty acid oxidation.[1]
References
- ↑ Yin W, Tsutsumi K (2003). "Lipoprotein lipase activator NO-1886". Cardiovascular Drug Reviews. 21 (2): 133–42. doi:10.1111/j.1527-3466.2003.tb00111.x. PMID 12847564.
This article is issued from Wikipedia - version of the 5/25/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.